FIELD: medicine.
SUBSTANCE: present invention refers to using pituitary adenylate cyclase-activating polypeptide (PACAP) in treating viral diseases and viral infectious diseases in aquatic organisms.
EFFECT: what is shown is the efficacy of PACAP either separately, or in a combination with an antiviral molecule, manifested in increasing a survival rate of fish and shell fish infected with viruses, wherein PACAP has been administered orally, injected or by immersing into baths; besides, it has been observed that the treated organisms preserve or increase weight as compared to the infected, however untreated organisms PACAP or PACAP containing combinations reduce a viral load in tissues and organs sensitive to viral infections, as shown by reserve transcription PCR.
18 cl, 3 tbl, 10 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF PACAP AS MOLECULAR ADJUVANT FOR VACCINES | 2012 |
|
RU2580294C2 |
| NEUROPEPTIDES FOR CULTURE OF AQUATIC ORGANISMS | 2006 |
|
RU2409027C2 |
| PERMANENT OMG CELL LINE FROM GONADS OF TROUT (ONCORHYNCHUS MYKISS) | 2012 |
|
RU2495120C1 |
| SERUM-FREE INTRACELLULAR PATHOGEN VACCINE | 2019 |
|
RU2818370C2 |
| ANTIVIRAL AGENT AGAINST HUMAN HERPESVIRUS TYPE I AND ENTEROVIRUS B | 2022 |
|
RU2798659C1 |
| METHOD OF TREATING VIRAL HEPATITIS C | 2012 |
|
RU2496512C1 |
| ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS-RELATED INFECTIONS | 2017 |
|
RU2753534C2 |
| AN ANTIVIRAL AGENT AGAINST SARS-COV-2 CORONAVIRUS | 2022 |
|
RU2788762C1 |
| MUTANT MYCOPLASMA HYOPNEUMONIAE STRAINS | 2013 |
|
RU2689671C2 |
| USE OF PEPTIDE THAT ENHANCES SECRETION OF SOMATOTROPIC HORMONE AS VACCINE ADJUVANT | 2017 |
|
RU2768134C2 |
